YOU WONT BELIEVE: 13 - What They Never Told You

2 Stocks That Could Be Long-Term Winners for Investors

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

StockNews.com · Aug 2, 2022

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com · Aug 1, 2022

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com · Jul 12, 2022

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

StockNews.com · Jun 23, 2022

5 Stocks Upgraded To "Strong Buy" Last Week

Investors’ concerns over the impending interest rate hikes are expected to keep the markets highly volatile in the near term. Therefore, it could be wise to invest in fundamentally-sound stocks Group 1 Automotive (GPI), Eli Lilly and Company (LLY), nVent Electric (NVT), Primo Water (PRMW), and Sanmina (SANM) that are…

StockNews.com · Jun 20, 2022

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Benzinga · Jun 14, 2022

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

Benzinga · Jun 10, 2022

3 Growth Stocks to Buy if You Think Inflation Has Peaked

A slightly lower consumer price index in April and expectations of a flat or lower CPI in May indicate inflation may have peaked. Yesterday, the major U.S. stock indices increased slightly as leading growth stocks rallied. Given this backdrop, we think it could be wise to invest in the shares…

StockNews.com · Jun 7, 2022

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Benzinga · Jun 7, 2022

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…

Benzinga · Jun 7, 2022